Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Edesa Biotech ( (EDSA) ) has issued an update.
Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common shares on the market, a move that could resonate well with investors looking for fresh opportunities. The sales will follow market prices and may be conducted on the Nasdaq Capital Market or other trading platforms. With a total market value of $3,870,000 available for sale, the company stands to pay a 3% commission on gross proceeds to Wainwright, while also covering certain expenses. Importantly, Edesa retains the flexibility to halt sales at any time, providing a strategic tool to navigate market conditions.
For detailed information about EDSA stock, go to TipRanks’ Stock Analysis page.
